Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 14;386(15):1475-1477.
doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita  1 , Noriko Kinoshita  2 , Seiya Yamayoshi  3 , Yuko Sakai-Tagawa  3 , Seiichiro Fujisaki  1 , Mutsumi Ito  3 , Kiyoko Iwatsuki-Horimoto  3 , Peter Halfmann  4 , Shinji Watanabe  1 , Kenji Maeda  2 , Masaki Imai  3 , Hiroaki Mitsuya  2 , Norio Ohmagari  2 , Makoto Takeda  1 , Hideki Hasegawa  1 , Yoshihiro Kawaoka  5
Affiliations

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

References

    1. World Health Organization. Weekly epidemiological update on COVID-19. February 1, 2022. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on...).
    1. CoVariants. Overview of variants/mutations. February 3, 2022. (https://covariants.org/per-variant).
    1. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. DOI: 10.1056/NEJMc2119407. - DOI - PMC - PubMed
    1. Uraki R, Kiso M, Imai M, et al. Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. January 19, 2022. (https://assets.researchsquare.com/files/rs-1240227/v1/43f2453c-851d-4f87...). preprint. - PubMed

MeSH terms

Substances

Supplementary concepts